Susquehanna International Group’s Aimmune Therapeutics AIMT Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2020
Q4 | – | Sell |
-263,500
| Closed | -$9.08M | – | 12115 |
|
|
2020
Q3 | $9.08M | Buy |
263,500
+163,900
| +165% | +$3.49M | ﹤0.01% | 2290 |
|
|
2020
Q2 | $1.66M | Sell |
99,600
-100
| -0.1% | -$1.7K | ﹤0.01% | 4827 |
|
|
2020
Q1 | $1.44M | Buy |
99,700
+50,800
| +104% | +$1.3M | ﹤0.01% | 4580 |
|
|
2019
Q4 | $1.64M | Sell |
48,900
-117,000
| -71% | -$3.27M | ﹤0.01% | 4652 |
|
|
2019
Q3 | $3.47M | Buy |
165,900
+127,700
| +334% | +$2.61M | ﹤0.01% | 3263 |
|
|
2019
Q2 | $795K | Sell |
38,200
-55,500
| -59% | -$1.14M | ﹤0.01% | 6208 |
|
|
2019
Q1 | $2.09M | Buy |
93,700
+82,500
| +737% | +$1.94M | ﹤0.01% | 3669 |
|
|
2018
Q4 | $268K | Sell |
11,200
-57,000
| -84% | -$1.47M | ﹤0.01% | 7208 |
|
|
2018
Q3 | $1.86M | Sell |
68,200
-13,700
| -17% | -$387K | ﹤0.01% | 4122 |
|
|
2018
Q2 | $2.2M | Sell |
81,900
-308,600
| -79% | -$9.44M | ﹤0.01% | 3849 |
|
|
2018
Q1 | $12.4M | Buy |
390,500
+308,300
| +375% | +$10.8M | ﹤0.01% | 1599 |
|
|
2017
Q4 | $3.11M | Buy |
82,200
+54,400
| +196% | +$1.76M | ﹤0.01% | 3178 |
|
|
2017
Q3 | $689K | Buy |
+27,800
| New | +$599K | ﹤0.01% | 5962 |
|
|
2017
Q1 | – | Sell |
-10,100
| Closed | -$207K | – | 10424 |
|
|
2016
Q4 | $207K | Buy |
+10,100
| New | +$206K | ﹤0.01% | 8609 |
|
Susquehanna International Group's AIMT Position: Q4 2020 in Review
Susquehanna International Group sold out of Aimmune Therapeutics (AIMT) in Q4 2020, closing a stake of 238,307 shares — an estimated $8.21M sold.
Susquehanna International Group first reported a position in AIMT in Q3 2015 and held it in 15 quarters. The position peaked at $8.21M in Q3 2020. 0 funds tracked by Wall St. Rank hold AIMT as of Q4 2020.
- Susquehanna International Group reported no remaining Aimmune Therapeutics position as of Q4 2020 after selling out during the quarter.
- Susquehanna International Group sold 238,307 Aimmune Therapeutics shares in Q4 2020, an estimated $8.21M.
- Susquehanna International Group first reported a position in Aimmune Therapeutics in Q3 2015 and held it in 15 quarters.
- Susquehanna International Group's Aimmune Therapeutics position peaked at $8.21M in Q3 2020.
- 0 funds tracked by Wall St. Rank held Aimmune Therapeutics as of Q4 2020.
Based on Susquehanna International Group's 13F filing for Q4 2020, filed 16 Feb 2021.